Overall rank by patents
#25,265
of 49,997 tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 13 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).
The verdict
According to USPTO PatentsView, Speclipse ranks #25,265 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 13 technology areas.
USPTO PatentsView assignee plate
Corpus R25265 · Foreign Corporation #25,265 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Solaris Oilfield Site Services Operating LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Speclipse · this assignee
34 score
3D Lighting… · lowest
7 score
What this shows Speclipse's Innovation Score is 33.9/100 (46th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Speclipse, Inc. is a focused PatentsView assignee: 13 CPC subclasses with 72.7% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2018. By volume, Speclipse sits between Solaris Oilfield Site Services Operating LLC and Spruce Biosciences, Inc..
Speclipse, Inc. shows 4 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Solaris Oilfield Site Services Operating LLC
11 patents
Solvay Solexis S.P.A.
11 patents
Sondex Wireline Limited
11 patents
Specialized Desanders Inc.
11 patents
Spectrum Optix Inc.
11 patents
SPF Technologies LLC
11 patents
Spinefrontier, Inc
11 patents
Spruce Biosciences, Inc.
11 patents
Speclipse, Inc.
11 patents
What this shows Speclipse holds 11 patents at rank #25,179, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #25,179 in granted patent volume.
Other assignees with the most granted patents in Speclipse's primary technology class.
Speclipse's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 46th percentile higher than 46% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 9.1% |
| 2019 | 3 | 27.3% |
| 2020 | 1 | 9.1% |
| 2021 | 1 | 9.1% |
| 2022 | 2 | 18.2% |
| 2023 | 1 | 9.1% |
| 2024 | 1 | 9.1% |
| 2025partial year | 1 | 9.1% |
Top 13 of 13 technology areas
Overall rank by patents
#25,265
of 49,997 tracked assignees
33.9 out of 100
What to do with this data
Speclipse, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.